Visit statistics

May our host count your visit? It then sets a cookie and notes the pages you read, your device and your country. We see only totals. The site works the same either way. What is recorded

Peptides Explained

Metabolic

AOD-9604

A piece of growth hormone, once tested as a diet pill. It failed in a big trial.

Not an authorised medicine

Short page. This is a short page. A full page with the complete evidence review is planned for version 1.1. The grades and regulatory status below are complete and sourced.

At a glance

Is it an approved medicine?
No Not approved as a medicine in the EU, the UK or the US.
Has it been tested in people?
Some Small trials in patients. No large trials published yet.
Is it allowed in sport?
No Banned in sport at all times. Anti-doping list (WADA), section S2
What is the biggest risk?
What is in a vial is unknown. Long-term safety was never studied. More about the risks

Status checked on . The details and sources are further down this page.

Stop and get help if you notice

  • Chest pain or tightness1,45
  • Hot, red, swollen or painful injection site42
  • Swollen face or throat, or trouble breathing44,1

If it is severe, call your local emergency number.

All warning signs, further down this page Warning signs for any peptide

The 30-second version

About 5 minutes for the short version; 10 with every detail open.

  • AOD-9604 is a lab-made copy of the last part of growth hormone. It is not an approved medicine.
  • A company tested it as a weight-loss pill. In a trial of 502 people, it did not work.
  • The full trial results were never published. We found no study of shots in people.
  • In 2024, US experts voted 12 to 0 against letting pharmacies make it.
  • It is banned in sport at all times.
Class
Metabolic
What it is
Growth hormone's last 15 building blocks, plus tyrosine
Developed for
Obesity, as a pill; stopped in 2007
Largest trial
502 adults, 24 weeks: weight loss not significant
Injected use studied?
No study in people found
Status in the EU
Not authorised
Tested in people
Some

Label facts, not dosing advice. Sources are in the sections below.

Last reviewed
Fat tissue under a microscope: many large, empty-looking round cells with thin purple walls.
Fat tissue under the microscope. AOD-9604 helped obese rodents lose fat; in people, weight loss was not shown. Photo: Berkshire Community College Bioscience Image Library, Connective Tissues: Adipose (Wikimedia Commons) CC0 1.0 Image details

Each section starts with the short answer. The rest is folded under “In detail”.

Evidence profile

Four separate questions. Not a score.

Human clinical evidence How far has it been tested in people?
Phase II (dose and early effect)
Preclinical volume How much laboratory and animal research exists?
Minimal
Source independence How many independent groups produced it?
One group dominates
Safety characterisation How well do we know the harms in humans?
Partial
In detail Why these grades: the reason for each step
Human clinical evidence
Phase 2 on our rubric. The developer ran six randomised, placebo-controlled trials, the largest in 502 adults with obesity for 24 weeks, but published only a safety summary. By the company's own report the large trial missed its main goal. The FDA found no study of injections or skin creams in people.
Preclinical volume
Minimal. Fewer than 10 primary animal or cell studies of AOD-9604 itself are on PubMed (search of 23 October 2026).
Source independence
Single group dominant. Almost all animal work comes from the Monash University group that made it and from the developer; one independent rabbit study exists.
Safety characterisation
Partial. About 900 people were enrolled in short company trials of pills and drips, reported only as a summary without numbers per group. Cancers reported in one trial were judged unrelated by the investigator; the FDA found the information insufficient to judge.

We never add these up. A compound can have a large animal literature from one laboratory and no human data at all — that is a specific situation, and a single number would hide it. How we grade evidence

In detail The molecule: amino-acid sequence and technical details
Amino-acid sequence16 amino acids

H–Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe–OH

Read from the N-terminus (start) to the C-terminus (end).

Modifications
position 1: Tyrosine added in front of growth hormone's last 15 building blocks (177-191)
Ring closures
7–14 (disulfide)
Full name
Tyr-hGH(177-191), a modified fragment of human growth hormone
Also called
AOD9604, Advanced Obesity Drug 9604
Class
Metabolic
Body systems
Metabolism
Formula
C78H123N23O23S2
Molecular mass
1,815.1 Da

What it actually is

What is AOD-9604?

A lab-made piece of growth hormone, first developed as a diet pill. It is not an approved medicine.
AOD-9604 comes from growth hormone, but does not act like it, and is not approved. What is known about the substance sold under this name, from the FDA's 2024 review, checked on 23 October 2026.
AOD-9604
Made in a lab?Yes A chain of 16 amino acids: growth hormone’s last 15, with a tyrosine added in front.1
Acts like growth hormone?No It did not bind growth hormone receptors in cells, and did not raise IGF-1 in trials.1,2
Approved as a medicine?No Not part of any FDA-approved drug; no EU record.1,3
Tested as an injection in people?No The FDA found no such study.1

The Australian company Metabolic Pharmaceuticals developed it in the late 1990s as an anti-obesity drug, and stopped in 2007.1 US clinics now market it, mostly as injections or pills, for weight loss, joints and anti-ageing.1

In detail The molecule, and the 'GRAS' claim

AOD-9604 is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a bridge between the two cysteines. Formula C78H123N23O23S2, mass 1815.1 g/mol.1,4 It is sold as a free base or an acetate salt, and the FDA found it not well characterised: no public tests for impurities, clumps, germs or bacterial toxins.1 PubChem lists “Tyr-somatostatin (177-191)” as a synonym. That is wrong: it is based on growth hormone (somatotropin), not somatostatin.4

“GRAS” is a US food term: generally recognised as safe. If a product description calls AOD-9604 GRAS, note that the FDA’s public list of GRAS notices has no entry for it.5 GRAS is about food, not medicines. In the EU, food means something meant to be swallowed, and medicines are excluded, so a product meant for injection is not a food.6

Proposed mechanism

How does it work?

Nobody knows its target. In obese rodents it increased fat breakdown.
The proposed causal chain, step by step

Each step is labelled with how well the link from the previous step is established.

  1. Step 1 Binding Hypothesised

    Its target is unknown

    The FDA states that its molecular target and mechanism remain unknown. Unlike growth hormone, it did not bind growth hormone receptors on cells in a dish.

  2. Step 2 Tissue response In animals

    More fat breakdown in obese rodents

    Obese mice and rats given AOD-9604 gained less weight and broke down more fat. Unlike growth hormone, it did not raise blood sugar in these animals.

  3. Step 3 Effect on the body In humans

    Weight loss in people: not shown

    In the largest trial, 502 adults with obesity on diet and exercise, weight loss at 12 weeks was not significantly different from placebo.

In detail What each step rests on

The animal results come almost entirely from the group that created it, and the FDA notes that none of these studies tested different doses or corrected its statistics for many comparisons.1,7,8 In obese mice, the effect needed the beta-3 receptor on fat cells, but the authors concluded that AOD-9604 does not act on it directly.7

What the evidence actually shows

Does it work?

No. In the largest trial, people did not lose clearly more weight than on a dummy pill.

In 502 adults, weight loss was no better than placebo

502

adults with obesity took part; at 12 weeks they had not lost clearly more weight

Who took part OPTIONS trial: daily pill for 24 weeks with diet and exercise (company report, quoted by the FDA) Source FDA Briefing Document1 Evidence Human trials

The maker gave up on it as a diet drug

2007

the year the maker said the results did not back it as a diet drug

What was counted Company announcement of 21 February 2007, quoted in the FDA's 2024 review Source FDA Briefing Document1

The FDA concluded that the evidence does not support it for obesity by any route.1 Claims about joints, bones or anti-ageing rest on, at most, animal studies.1,9

In detail Every study in one table

6 studies: 2 in humans, 3 in animals, 0 in cells, 1 reviews or other.

Studies discussed on this page
Study Species n Design Funding Research group What it found What it did not show
Ng et al. 2000 8 Rats not reported Animal experiment (controlled) Not disclosed Originating group Obese rats given AOD-9604 by mouth for 19 days gained less than half as much weight as untreated rats. Unlike growth hormone, it did not make them resistant to insulin. Rats, from the group that created it; no dose-response; statistics not corrected for multiple tests (FDA).
Heffernan et al. 2001 7 Mice not reported Animal experiment (controlled) Not disclosed Originating group In obese mice, 14 days of injections into the belly cavity reduced body weight and fat; mice lacking the beta-3 receptor did not respond the same way. Mice, originating group; no dose-response tested.
U.S. Food and Drug Administration 2007 1 Humans 502 Phase II trial (controlled, blinded) Industry Originating group In 502 randomised adults with obesity taking a daily pill for 24 weeks with diet and exercise, weight loss was not significantly greater than with placebo; the company stopped development for obesity. Known only from the company's stock-exchange report, as quoted by the FDA; never published in a journal.
Stier et al. 2013 2 Humans not reported Phase II trial (controlled, blinded) Industry Originating group A summary of six company trials (drips and pills) reported no effect on IGF-1 or blood sugar and no antibodies against the peptide in the people tested. Written by people working for the developer; no numbers of side effects per group; efficacy not reported.
Vanhee et al. 2014 18 — not reported Product testing Government Independent group A Belgian public-health laboratory identified AOD-9604 in unknown preparations seized by the authorities. A short report on seized products; it shows the substance is on the illegal market, not what typical products contain.
Kwon & Park 2015 9 Rabbits 32 Animal experiment (controlled) Not disclosed Independent group In 32 rabbits with induced knee osteoarthritis, joint injections of AOD-9604 led to less cartilage damage than saline, and more so when combined with hyaluronic acid. Rabbits only; one independent group; joint use was never tested in people.

Three smaller trials, in 23, 16 and 36 people with obesity, found no significant weight loss against placebo; a 12-week trial in 300 people is known only from a meeting abstract that reported small differences.1 All human trials were run and paid for by the developer, and the authors of the safety summary worked for it or advised it.1,2

Regulatory status

Is it legal?

It is not an approved medicine, and it is banned in sport.
Not approved where we looked. US experts voted against it. Status in the Netherlands, the EU and the US, and in sport, checked on 23 October 2026.
Netherlands and the EUUnited States
Approved as a medicine?No No EU or Dutch authorisation.3,10No Not part of any FDA-approved drug.1
Legal to supply as a medicine?No Dutch law forbids supplying a medicine without a marketing authorisation.11No FDA advisers voted 12–0 against letting pharmacies make it.12
Allowed in sport?No Banned at all times, named in section S2.13,14No The same worldwide rule.13
In detail Status in each country, and in sport
Regulatory status by jurisdiction
Jurisdiction Status Note Checked
European Union Not authorised Not authorised. No EMA record and no European Pharmacopoeia monograph. 3,46,1
Netherlands Not authorised Not authorised. Supplying a medicine without a marketing authorisation is prohibited. 10,11
United States Not authorised Not FDA-approved. In December 2024 FDA advisers voted 12–0 against adding it to the 503A list. No FDA GRAS notice exists. 1,12,15,47
Sport (WADA) Prohibited in sport · S2, at all times Banned at all times: named in S2 as a growth hormone fragment. 13,14

All statuses were checked on 23 October 2026. On 4 December 2024 the FDA’s Pharmacy Compounding Advisory Committee voted 12 to 0 that neither form should go on the list of substances US pharmacies may compound, as FDA staff had proposed.12,1 The FDA had placed AOD-9604 in category 2, for substances that may pose significant safety risks; the nominations were withdrawn.15

WADA names AOD-9604 in section S2 as a growth hormone fragment, banned at all times.13,14 In Germany it is listed in the Anti-Doping Act, which forbids buying, possessing or bringing into the country more than a small amount for doping in sport.16,17 Australia controls it as a performance- and image-enhancing drug.1

Risk profile

What are the risks?

Its long-term safety was never studied. Products sold online may hold something else.
Some warning signs appeared in small studies. None was followed up. What the FDA found in the published summaries and animal studies, as of 23 October 2026.
Possible harmShown in people?
Chest tightnessYes Once, severe, in a drip study; judged possibly related.1
CancerUnknown Four cancers in one 12-week trial were judged unrelated; the FDA found too little information to judge.1
Effects on bone or liverUnknown Changes in bone markers in rats and liver cells in monkeys.1
An immune reaction to an injectionUnknown The FDA’s concern for injected peptides; not studied.1
In detail What was reported, and why the gaps matter

In the company trials, the most common complaints were headache, tiredness and dizziness with drips, and headache, diarrhoea and wind with pills; mild or moderate euphoria was reported 5 times on the drug and never on placebo.1 In a 26-week rat study, a bone marker, osteocalcin, changed with the dose; in a 9-month monkey study, small changes appeared in liver cells. The FDA calls both possible safety signals.1 Tests for damage to genes gave unclear results.1

All of this concerns the developer’s product. AOD-9604 has been found in seized products in Belgium and in confiscated vials in the US.18,19 See product risk.

If someone is going to do this anyway

This section exists to reduce harm. It gives no doses, schedules or sourcing advice, and it is not a recommendation to use this compound.

How can someone lower the risk?

Check the vial first, bring a doctor in, and know when to stop.

If your product did not come from a pharmacy: check before you use it

These checks can show that something is wrong. None of them can show that a product is good or free of germs.20,21,22

Tick each box when you have checked it.

  • The seal and the vial are whole

    A broken cap or seal, or a cracked vial, can let germs in. Then do not use it.23,24,25

  • The label shows the name, amount, batch number and expiry date

    In the EU, a medicine must show all four, even on a small vial. If one is missing, or the date has passed, that is a warning sign. Take a photo of the label.26,23

  • For AOD-9604

    Check which form the label names. AOD-9604 is sold as a free base or an acetate salt. The FDA treats them as different substances.1

  • It looks right

    A liquid, or a powder after mixing, should be clear and colourless, with no bits. Is it cloudy, has it changed colour, or do you see bits? Then do not use it.27,28

  • A lab report proves little if:

    • its batch number is not the one on your vial;
    • it does not name the lab, or has no date or signature;
    • it shows only purity (HPLC), with no test of what it is, such as mass spectrometry;
    • it has no test for germs (sterility) or for toxins from germs (endotoxin).

    Even a full report covers only one sample. A report from the seller comes from someone who gains if it looks good. It cannot show that your vial is clean.29,30,31,32,33

    What a certificate of analysis shows, and what it does not

  • It was kept as the label says

    Heat, freezing and sunlight can damage a peptide. Did it arrive warm, or was it frozen? Then do not use it. Often nobody can tell you how it was kept on the way. If you cannot know, you cannot rule out damage. When in doubt, throw it out.28,34,35,25

    When to throw a vial away

  • Clean steps, and a new sterile needle and syringe every time

    Wash your hands and wipe the rubber top with alcohol. Never share a needle, a syringe or a vial.25,36,34

    Sterile technique, step by step

  • Keep the vial, its label and any papers

    Keep them, even when the vial is empty, until you know you feel well. If you need a doctor, bring them. A lab can test what was inside.37,38

    If something goes wrong

  • Tell a doctor, and agree which checks fit you

    A doctor can help you choose blood tests that fit what you use. In the Netherlands, your doctor must keep what you say private.39,40,41

    Which checks matter, and whyTalking to your doctor

  • Know the warning signs before you start

    Spreading redness, fever, a swollen face or hard breathing need help fast. If it is severe, call your local emergency number.42,43,44

    All warning signs, and how fast to act

When to stop and get help

Sources 45, 42, 44, 1

Stop-now warning signs

Call your local emergency number now

  • Confusion or slurred speech, very fast breathing, or pale, blue or blotchy skin, often with fever or shivering These can be signs of sepsis: the body's reaction to an infection has started to damage its own organs.
  • Fainting and not waking up within a minute, or fainting with chest pain, a racing heart or a fit This can be a dangerous heart rhythm or a severe allergic reaction.
  • Pain at the injection spot that is much worse than it looks, or dark, purple or grey patches or blisters there This can be a rare, fast-spreading infection of the deep layers under the skin (necrotising fasciitis).
  • Swelling of the lips, tongue or throat, trouble breathing or swallowing, wheezing, a hoarse voice, or feeling faint, soon after an injection This can be a severe allergic reaction (anaphylaxis), which is life-threatening and gets worse very quickly.
  • Pain, pressure or tightness in the chest, or pain that spreads to the arm, neck, jaw or back This can be a heart attack, which needs treatment in hospital straight away.
  • Sudden, severe shortness of breath: gasping, or not able to finish a sentence This can be a serious problem with the heart, the lungs or an allergic reaction.
  • A racing, pounding or irregular heartbeat that does not settle, or that comes with chest pain, breathlessness or fainting This can be a dangerous heart rhythm.
  • A sudden, severe headache with blurred vision, chest pain, confusion or vomiting Blood pressure may be dangerously high, which can damage the brain, heart, kidneys and eyes.
  • An erection that lasts more than 3 hours, or a painful erection that will not go down Blood trapped in the penis can damage it for good if it is not treated quickly.

Get medical help today

  • Fever, shivering or feeling very ill in the days after an injection Germs from the needle, the skin or the product may have reached your blood. If you also have a fast heartbeat or fast breathing, call your local emergency number.
  • Redness, heat, swelling or pain around the injection spot that keeps growing or getting worse This can be a skin infection (cellulitis), which needs antibiotics before it spreads.
  • Red lines that run from the injection spot towards the armpit or groin The infection may be spreading along the lymph vessels, and from there into the blood. If you also have a fever with a fast heartbeat or fast breathing, call your local emergency number.
  • A painful, warm lump that fills with pus This is probably an abscess: it often needs draining by a doctor, so do not squeeze it.
  • You were pricked by a needle that someone else had used Blood on a used needle can pass on HIV and hepatitis B or C, and preventive treatment works best within hours.

Stop and contact a doctor

  • You fainted, but woke up quickly and now feel well Fainting is often harmless, but a doctor should check the cause.
  • A new mole, or a mole that changes size, shape or colour, itches or bleeds A changing mole can be skin cancer, and tanning peptides such as melanotan II have been linked to new and changing moles in case reports.
  • A lump at an injection spot that does not go away, or keeps growing A doctor should check whether it is an abscess, a reaction to the product or something else.
  • An itchy, raised rash, or puffy eyes or lips, while breathing stays normal Your body may be reacting to the product, and using it again can bring the reaction back.
  • Palpitations that keep coming back, even if they pass and you then feel well A doctor can check whether your heart rhythm is normal.
In detail Checks that make sense

A doctor can help you decide which checks fit you (see talking to your doctor):

  • Any new lump, changing mole or unusual bleeding checked, because cancers were reported in one trial and the link could not be judged.1
  • Anti-doping rules, if you compete: it is banned at all times and can be detected.13,19

For injecting, see sterile technique.

Sources

Every claim on this page links to one of these sources. Scholarly sources link to their DOI; regulatory sources to the regulator's own page.

In detail All 47 sources, numbered as in the text
  1. U.S. Food and Drug Administration (2024). FDA Briefing Document: Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate) for Inclusion on the 503A Bulk Drug Substances List, Pharmacy Compounding Advisory Committee, 4 December 2024. Regulator fda.gov — accessed 23 October 2026 ↩
  2. Stier H, Vos E, Kenley D (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism 3:7-15. Research article doi:10.4021/jem157w ↩
  3. European Medicines Agency (2026). Medicines data download (JSON report of all EPARs: authorised, refused, withdrawn and suspended medicines). Dataset ema.europa.eu — accessed 20 October 2026 ↩
  4. National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 71300630, AOD-9604. PubChem. Dataset pubchem.ncbi.nlm.nih.gov — accessed 23 October 2026 ↩
  5. U.S. Food and Drug Administration (2026). GRAS Notice Inventory searches, 23 October 2026: AOD-9604, 9604, nicotinamide mononucleotide, nicotinamide riboside, copper. FDA Human Foods Program. Dataset hfpappexternal.fda.gov — accessed 23 October 2026 ↩
  6. European Parliament and Council of the European Union (2002). Regulation (EC) No 178/2002 laying down the general principles and requirements of food law, Article 2 (definition of food). Official Journal of the European Communities, L 31. Law eur-lex.europa.eu — accessed 23 October 2026 ↩
  7. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 142:5182-5189. Research article doi:10.1210/endo.142.12.8522 ↩
  8. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research 53:274-278. Research article doi:10.1159/000053183 ↩
  9. Kwon DR, Park GY (2015). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical and Laboratory Science 45:426-432. Research article PMID 26275694 ↩
  10. College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2026). Geneesmiddeleninformatiebank (database of medicines authorised in the Netherlands). Regulator geneesmiddeleninformatiebank.nl — accessed 20 October 2026 ↩
  11. Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 40 (verbod op geneesmiddelen zonder handelsvergunning, en de uitzonderingen). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl — accessed 22 October 2026 ↩
  12. U.S. Food and Drug Administration (2025). Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. Regulator fda.gov — accessed 22 October 2026 ↩
  13. World Anti-Doping Agency (2025). World Anti-Doping Code International Standard: Prohibited List 2026. Regulator wada-ama.org — accessed 20 October 2026 ↩
  14. World Anti-Doping Agency (2026). World Anti-Doping Code International Standard: Prohibited List 2027 (in effect 1 January 2027). Regulator wada-ama.org — accessed 20 October 2026 ↩
  15. U.S. Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Regulator fda.gov — accessed 20 October 2026 ↩
  16. Bundesministerium der Justiz (2023). Gesetz gegen Doping im Sport (Anti-Doping-Gesetz – AntiDopG), Anlage (zu § 2 Absatz 3). gesetze-im-internet.de. Law gesetze-im-internet.de — accessed 20 October 2026 ↩
  17. Bundesministerium der Justiz (2026). Gesetz gegen Doping im Sport (Anti-Doping-Gesetz – AntiDopG), § 2 Unerlaubter Umgang mit Dopingmitteln. gesetze-im-internet.de. Law gesetze-im-internet.de — accessed 20 October 2026 ↩
  18. Vanhee C, Moens G, Deconinck E, De Beer JO (2014). Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604. Drug Testing and Analysis 6:964-968. Research article doi:10.1002/dta.1687 ↩
  19. Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D (2015). Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis 7:31-38. Research article doi:10.1002/dta.1715 ↩
  20. Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). Online medicijnen. Regulator igj.nl — accessed 22 October 2026 ↩
  21. Ashraf AR, Mackey TK, Vida RG, Kulcsár G, Schmidt J, Balázs O, Domián BM, Li J, Csákó I, Fittler A (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research 26:e65440. Research article doi:10.2196/65440 ↩
  22. Smith RM, Schaefer MK, Kainer MA, Wise M, Finks J, et al. (2013). Fungal infections associated with contaminated methylprednisolone injections. The New England Journal of Medicine 369:1598-1609. Research article doi:10.1056/NEJMoa1213978 ↩
  23. U.S. Food and Drug Administration (2020). BeSafeRx: Considering an Online Pharmacy?. Regulator fda.gov — accessed 22 October 2026 ↩
  24. Hospira, Inc. / DailyMed (National Library of Medicine) (2026). Sterile Water for Injection, USP: prescribing information. Official product information dailymed.nlm.nih.gov — accessed 20 October 2026 ↩
  25. World Health Organization (2010). WHO best practices for injections and related procedures toolkit (WHO/EHT/10.02). World Health Organization, Geneva. Report who.int — accessed 20 October 2026 ↩
  26. European Parliament and Council of the European Union (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text). Official Journal of the European Communities, L 311. Law eur-lex.europa.eu — accessed 20 October 2026 ↩
  27. U.S. Food and Drug Administration / DailyMed (National Library of Medicine) (2026). EGRIFTA SV (tesamorelin for injection): prescribing information and instructions for use. Official product information dailymed.nlm.nih.gov — accessed 20 October 2026 ↩
  28. European Medicines Agency (2026). Wegovy (semaglutide): EPAR — overview and product information. Official product information ema.europa.eu — accessed 20 October 2026 ↩
  29. European Medicines Agency (ICH) (2000). ICH Q7 Good manufacturing practice for active pharmaceutical ingredients (CPMP/ICH/4106/00). European Medicines Agency, scientific guideline. Regulator ema.europa.eu — accessed 22 October 2026 ↩
  30. European Medicines Agency, CHMP and CVMP (2025). Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025). European Medicines Agency. Regulator ema.europa.eu — accessed 22 October 2026 ↩
  31. U.S. Food and Drug Administration (2026). FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  32. U.S. Food and Drug Administration (2026). FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  33. Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E (2018). Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta 188:795-807. Research article doi:10.1016/j.talanta.2018.06.023 ↩
  34. U.S. Food and Drug Administration (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. Regulator fda.gov — accessed 20 October 2026 ↩
  35. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research 27:544-575. Review doi:10.1007/s11095-009-0045-6 ↩
  36. Centers for Disease Control and Prevention (2024). Preventing Unsafe Injection Practices. Regulator cdc.gov — accessed 20 October 2026 ↩
  37. NHS (2025). Poisoning. Web page nhs.uk — accessed 22 October 2026 ↩
  38. Antonacci G, Bortignon E, Bolognesi M, Piano SS, Cadore A, Camuffo L, Venturini F, Faoro S, Favretto D, Romano A, Mengato D (2026). Hypoglycaemic coma induced by a falsified semaglutide product: a case report. European Journal of Hospital Pharmacy 33:486-489. Research article doi:10.1136/ejhpharm-2025-004656 ↩
  39. Thuisarts.nl (Nederlands Huisartsen Genootschap, NHG) (2024). Ik ga naar de huisarts: wat kan ik van tevoren doen en verwachten?. Web page thuisarts.nl — accessed 22 October 2026 ↩
  40. Department of Health, Victoria (Australia), Chief Health Officer (2026). Toxicity linked to unapproved peptide product labelled Retatrutide (health alert). Regulator health.vic.gov.au — accessed 22 October 2026 ↩
  41. KNMG (Royal Dutch Medical Association) (2024). Medisch beroepsgeheim: wat en waarom. Web page knmg.nl — accessed 20 October 2026 ↩
  42. NHS (England) (2024). Cellulitis. Web page nhs.uk — accessed 20 October 2026 ↩
  43. NHS (England) (2026). Sepsis. Web page nhs.uk — accessed 20 October 2026 ↩
  44. NHS (England) (2023). Anaphylaxis. Web page nhs.uk — accessed 20 October 2026 ↩
  45. NHS (England) (2023). Chest pain. Web page nhs.uk — accessed 20 October 2026 ↩
  46. European Medicines Agency (2026). Medicines (search of centrally authorised medicines and EPARs). Regulator ema.europa.eu — accessed 20 October 2026
  47. U.S. Food and Drug Administration (2026). openFDA Drugs@FDA queries, 23 October 2026: prezatide, GHK, copper tripeptide, AOD-9604, AOD9604, hexarelin, examorelin, nicotinamide riboside, nicotinamide mononucleotide, nadide, nicotinamide adenine dinucleotide, elamipretide. openFDA. Dataset api.fda.gov — accessed 23 October 2026